Evidence map›Paper›PMID 28319654›Full record

ArticleProteomics. Clinical applications2017

An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.

Li Yang, Tessandra Stewart, Min Shi, Gwenael Pottiez, Romel Dator, Rui Wu, Patrick Aro, Robert J Schuster, Carmen Ginghina, Catherine Pan and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics. Clinical applications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01720810 (Pacific Northwest Udall Center), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01720810 unknown statusnot on this map

Pacific Northwest Udall Center (PANUC) Clinical Core

TypeobservationalSponsorUniversity of WashingtonRan2010 to 2025Enrolled2,000ConditionsParkinson Disease, Cognitive Impairment
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Li YangDepartment of Pathology, University of Washington, Seattle, WA, USA.
Tessandra StewartDepartment of Pathology, University of Washington, Seattle, WA, USA.
Min ShiDepartment of Pathology, University of Washington, Seattle, WA, USA.
Gwenael PottiezDepartment of Pathology, University of Washington, Seattle, WA, USA.
Romel DatorDepartment of Pathology, University of Washington, Seattle, WA, USA.
Rui WuDepartment of Pathology, University of Washington, Seattle, WA, USA.
Patrick AroDepartment of Pathology, University of Washington, Seattle, WA, USA.
Robert J SchusterDepartment of Pathology, University of Washington, Seattle, WA, USA.
Carmen GinghinaDepartment of Pathology, University of Washington, Seattle, WA, USA.
Catherine PanDepartment of Pathology, University of Washington, Seattle, WA, USA.
Yuqian GaoPacific Northwest National Laboratory, Richland, WA, USA.
Weijun QianPacific Northwest National Laboratory, Richland, WA, USA.
Cyrus P ZabetianParkinson's Disease Research and Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Shu-Ching HuDepartment of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
Joseph F QuinnDepartment of Neurology, Oregon Health and Science University, Portland, OR, USA.
Jing ZhangDepartment of Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-3656-1112
University of Washington · USPacific Northwest National Laboratory · USOregon Health & Science University · USUniversity of Puget Sound · US

Funding

Udall Center Director's meeting poster awardP50NS062684 · NINDS · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 2009 to 2020
$18.3M
Large Scale Biomarker Discovery and Validation for Parkinsons DiseaseU01NS082137 · NINDS · UNIVERSITY OF WASHINGTON · PI ZHANG, JING · 2012 to 2016
$6.0M
Peptide Biomarkers for Parkinson DiseaseU01NS091272 · NINDS · UNIVERSITY OF WASHINGTON · PI SHI, MIN · 2016 to 2020
$2.1M
Using Multiplex Families to map Genes that Modify Susceptibility and Age at OnsetR01NS065070 · NINDS · UNIVERSITY OF WASHINGTON · PI ZABETIAN, CYRUS P · 2009 to 2012
$2.0M
NINDS NIH HHS P50 NS062684NINDS NIH HHS R01 NS065070NINDS NIH HHS U01 NS082137NINDS NIH HHS U01 NS091272
6 · The paper itself

Abstract

aimThe alpha-synuclein (α-syn) level in human cerebrospinal fluid (CSF), as measured by immunoassays, is promising as a Parkinson's disease (PD) biomarker. However, the levels of total α-syn are inconsistent among studies with large cohorts and different measurement platforms. Total α-syn level also does not correlate with disease severity or progression. Here, the authors developed a highly sensitive MRM method to measure absolute CSF α-syn peptide concentrations without prior enrichment or fractionation, aiming to discover new candidate biomarkers.

resultsSix peptides covering 73% of protein sequence were reliably identified, and two were consistently quantified in cross-sectional and longitudinal cohorts. Absolute concentration of α-syn in human CSF was determined to be 2.1 ng/mL. A unique α-syn peptide, TVEGAGSIAAATGFVK (81-96), displayed excellent correlation with previous immunoassay results in two independent PD cohorts (p < 0.001), correlated with disease severity, and its changes significantly tracked the disease progression longitudinally.

conclusionsAn MRM assay to quantify human CSF α-syn was developed and optimized. Sixty clinical samples from cross-sectional and longitudinal PD cohorts were analyzed with this approach. Although further larger scale validation is needed, the results suggest that α-syn peptide could serve as a promising biomarker in PD diagnosis and progression.

Indexed as

Disease ProgressionAdultAgedalpha-SynucleinFemaleHumansMaleMiddle AgedParkinson Diseasealpha-Synucleinalpha-synuclein (α-syn)DiagnosisMRMParkinson's diseaseProgression

Identifiers

PMID28319654
PMCPMC5540649
OpenAlexW2599386410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.